Mitochondria Targeted O 2 Economizer to Alleviate Tumor Hypoxia for Enhanced Photodynamic Therapy

Ping Yuan,Fu‐An Deng,Yi‐Bin Liu,Rong‐Rong Zheng,Xiao‐Na Rao,Xiao‐Zhong Qiu,Da‐Wei Zhang,Xi‐Yong Yu,Hong Cheng,Shi‐Ying Li
DOI: https://doi.org/10.1002/adhm.202100198
IF: 10
2021-05-03
Advanced Healthcare Materials
Abstract:<p>Photodynamic therapy (PDT) often suffers from the exacerbated tumor hypoxia and the heterogeneous distribution of photosensitizers, leading to an inefficient ROS productivity and availability. In this work, a mitochondria targeted O<sub>2</sub> economizer (designated as Mito‐OxE) is developed to improve PDT efficiency by alleviating tumor hypoxia and enhancing the subcellular localization of photosensitizers. Specifically, the photosensitizer of protoporphyrin IX (PpIX) is modified with the hydrophilic polyethylene glycol and the lipophilic cation of triphenylphosphine (TPP) to fabricate the biocompatible mitochondria targeted photosensitizers (designated as Mito‐PSs). And Mito‐OxE is prepared by using Mito‐PSs to load the mitochondrial oxidative phosphorylation inhibitors of atovaquone (ATO). Benefiting from the targeting capability of TPP, Mito‐OxE can selectively accumulate in mitochondria after cellular uptake. Subsequently, the mitochondrial respiration would be suppressed to with the participation of ATO, resulting in a local hypoxia mitigation for enhanced PDT. Compared with Mito‐PSs, Mito‐OxE maximizes the therapeutic effect against hypoxic tumors under light irradiation. This design of mitochondria targeted O<sub>2</sub> economizer would advance the development of targeted drug delivery system for effective PDT regardless of hypoxic microenvironment.</p>
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?